 |
市場調査レポート
商品コード
1441338
エピジェネティクスの世界市場規模、シェア、成長分析、製品タイプ別、技術別、用途別-産業予測、2023～2030年Global Epigenetics Market Size, Share, Growth Analysis, By Product type(Reagents, Kits), By Technology(DNA Methylation, Histone Methylation), By Application(Oncology, Cardiovascular Diseases) - Industry Forecast 2023-2030 |
||||||
| エピジェネティクスの世界市場規模、シェア、成長分析、製品タイプ別、技術別、用途別-産業予測、2023～2030年 |
|
出版日: 2024年02月17日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
エピジェネティクスの世界市場規模は2022年に13億6,000万米ドルと評価され、2023年の16億米ドルから2031年には47億米ドルに成長し、予測期間（2024～2031年）のCAGRは14.8%で成長する展望です。
世界のエピジェネティクス市場は、ゲノム研究の進歩やエピジェネティクスメカニズムの理解の深まりにより大きな成長を遂げており、近年の世界のエピジェネティクス業界における消費者の嗜好やニーズの変化につながっています。エピジェネティクスは、基礎となるDNA配列を変えることなく遺伝子の活性を変化させる研究であり、多くの生物学的プロセスや疾患にとって重要です。神経学、心臓病学、腫瘍学、その他の治療セグメントにおける応用の拡大が市場を牽引しています。エピジェネティクスの3つの主要研究セグメントには、ノンコーディングRNA制御、ヒストン修飾、DNAメチル化が含まれます。エピジェネティクス市場は、標的治療や個別化医療に対するニーズの高まりにより、さらなる成長が見込まれています。最先端の技術とソリューションを提供するため、同事業の主要企業は研究開発に投資しており、これが世界のエピジェネティクス市場全体の成長と進化に貢献しています。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
エピジェネティクスの世界市場：製品タイプ別
- 市場概要
- 試薬
- キット
- 機器
- 酵素
- サービス
エピジェネティクスの世界市場：技術別
- 市場概要
- DNAメチル化
- ヒストンのメチル化
- ヒストンのアセチル化
- マイクロRNA修飾
- その他
エピジェネティクスの世界市場：用途別
- 市場概要
- 腫瘍学
- 心血管疾患
- 代謝性疾患
- 神経学的障害
- 免疫学
エピジェネティクスの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- AbbVie Inc.
- AstraZeneca PLC
- Bayer AG
- BeiGene Ltd.
- Bristol Myers Squibb Company
- Epizyme, Inc.
- GlaxoSmithKline PLC
- Incyte Corporation
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Limited
- Targovax, Inc.
- Vertex Pharmaceuticals Incorporated
- Vivid Biosciences Inc.
- Zymeworks Inc.
Global Epigenetics Market size was valued at USD 1.36 billion in 2022 and is poised to grow from USD 1.6 billion in 2023 to USD 4.7 billion by 2031, growing at a CAGR of 14.8% during the forecast period (2024-2031).
The Global Epigenetics Market is experiencing significant growth due to the advances in genomic research and a greater comprehension of epigenetic mechanisms, leading to changes in consumer preferences and needs in the worldwide epigenetics industry in recent years. Epigenetics is the study of heritable modifications to gene activity without changing the underlying DNA sequence, and it is important for many biological processes and disorders. Growing applications in neurology, cardiology, oncology, and other therapeutic areas are driving the market. Three main areas of study in epigenetics include non-coding RNA regulation, histone modification, and DNA methylation. The market for epigenetics is anticipated to grow further due to the growing need for targeted medicines and personalized medicine. In order to bring cutting-edge technology and solutions, major players in the business are spending in research and development, which helps the overall growth and evolution of the global epigenetics market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Epigenetics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Epigenetics Market Segmental Analysis
There are four main segments in the worldwide Epigenetics Market: product type, technology, application, and region. It is separated into reagents, kits, instruments, enzymes, and services according to kind. It is divided into two categories according to technology: additional epigenetic alterations and microRNA modification, and histone acetylation, DNA methylation, and histone methylation. It is divided into categories according to application, including immunology, neurological disorders, metabolic diseases, cardiovascular diseases, and oncology. The market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa based on geographic factors.
Drivers of the Global Epigenetics Market
A major driver in this market is growing understanding of how essential epigenetic mechanisms are for controlling gene expression and affecting a range of biological functions. The demand for epigenetic tools and technologies has increased due to this increased understanding, which has spurred a boom in research activity across the academic, pharmaceutical, and biotechnology sectors. Furthermore, there is a greater emphasis on customized medicine due to the increased prevalence of chronic illnesses like cancer and neurological disorders, where epigenetics is essential in determining the best course of treatment.
Restraints in the Global Epigenetics Market
The high cost of advanced epigenetic technologies is one of the primary market barriers, preventing wider acceptance and accessibility, especially in areas with limited resources. The regulatory hurdles posed by ethical considerations and data privacy issues in epigenetic research have an impact on the rate of innovation. In addition, challenges to a smooth incorporation into clinical practice include the difficulty of interpreting epigenetic data and the absence of standardized analytical techniques..
Market Trends of the Global Epigenetics Market
The growing use of epigenetic insights in customized medicine is propelling the creation of specific treatments for a range of illnesses. Research activities are becoming more precise and efficient as a result of the integration of artificial intelligence and machine learning in the processing of large epigenomic datasets. Furthermore, non-invasive epigenetic diagnostics-which use tools like liquid biopsies to detect diseases like cancer early-are receiving more attention. With the increasing popularity of epigenome editing tools, researchers can now alter particular epigenetic marks, creating new opportunities for therapeutic interventions.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Epigenetics Market by Product type
- Market Overview
- Reagents
- Kits
- Instruments
- Enzymes
- Services
Global Epigenetics Market by Technology
- Market Overview
- DNA Methylation
- Histone Methylation
- Histone Acetylation
- MicroRNA Modification
- and Other Epigenetic Modifications
Global Epigenetics Market by Application
- Market Overview
- Oncology
- Cardiovascular Diseases
- Metabolic Diseases
- Neurological Disorders
- Immunology
Global Epigenetics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Epizyme, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Seattle Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Targovax, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vivid Biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zymeworks Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
